RCS - Cambridge Cognition - New data demonstrates effectiveness of AQUA

Cambridge Cognition HoldingsAnnouncement

31/10/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241031:nRSe3115Ka&default-theme=true

RNS Number : 3115K  Cambridge Cognition Holdings PLC  31 October 2024

 

 

31 October 2024

 

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

 

 

Cambridge Cognition Addressing Inconsistencies in CNS Clinical Trials with
Advanced Quality Review Solutions

Presentation of new data demonstrates effectiveness of proprietary AQUA

 

Cambridge Cognition, a leading technology company specialising in digital
health products that advance brain health research and treatment, announces
the recent presentation of new data demonstrating the effectiveness of the
Company's Automated Quality Assurance product, ("AQUA").

 

Central nervous system ("CNS") clinical trials often depend on
rater-administered assessments, like Clinical Dementia Rating ("CDR") and
Alzheimer's Disease Assessment Scale-Cognitive Subscale ("ADAS-Cog"), as key
endpoints. Unlike quantitative biomarkers, which have clear, measurable
values, these outcomes are subjective and can be affected by the rater's
judgment, training and motivations(1,2). Without proper training, even
experienced clinicians often disagree on scoring leading to frequent
errors(3).

 

Traditional quality assurance for clinical outcome assessments ("COAs") relies
on expert raters who must be trained prior to administering the tasks.
Cambridge Cognition is confident that, given the lack of standardisation, the
heavy utilisation on manual quality control and the high cost and time burden,
there is an urgent need for a scalable, cost-effective alternative to enhance
measurement accuracy and reduce variability.

 

Cambridge Cognition launched its proprietary product in 2023.  AQUA analyses
the audio recording of CNS clinical interviews and detects deviations in
administration and scoring by the rater.

 

Dr Rachel Newsome, Product Manager at Cambridge Cognition recently presented
new data(4) at the International Society for CNS Clinical Trials and
Methodology ("ISCTM") conference. AQUA demonstrated strong alignment with
expert reviewers on key quality indicators of CDR recordings in an Alzheimer's
disease trial, showcasing its ability to enhance COA review processes and
offers an efficient solution to support central monitoring.

 

Cambridge Cognition believes that AQUA provides a scalable solution, which
marks a significant advancement in improving quality assurance for CNS
clinical trials

 

Dr Rachel Newsome, Product Manager commented: "We are excited by the reception
that our new data received at the prestigious ISCTM conference. Our innovative
quality review solution accelerates quality reviews, improves consistency by
reviewing 100% of assessments in a trial, and significantly reduces costs,
which ultimately helps clinical trials to succeed."

 

Dr Steven Powell, Chair of Cambridge Cognition, added: "We are encouraged by
the progress of the AQUA product and we are confident that it can meet the
clear market need to implement automated processes within quality control in
clinical trials."

 

 

1.   Kobak KA, Kane JM, Thase ME, Nierenberg AA. Why do clinical trials
fail? The problem of measurement error in clinical trials: Time to test new
paradigms? J Clin Psychopharmacol. 2007;27(1):1-5.

 

2.   Walton MK, Powers JH 3rd, Hobart J, Patrick D, Marquis P, Vamvakas S,
et al. Clinical outcome assessments: Conceptual foundation-report of the ispor
clinical outcomes assessment - emerging good practices for outcomes research
task force. Value Health. 2015,18(6):741-52.

3.   Wilson JT, Slieker FJ, Legrand V, Murray G, Stocchetti N, Maas AI.
Observer variation in the assessment of outcome in traumatic brain injury:
Experience from a multicenter, international randomized clinical trial.
Neurosurgery. 2007;61(1):123-8.

4.   Newsome, RN, Analytical validation of a novel quality assurance
approach for COAs in Alzheimer's Disease clinical trials, CNS Clinical Trials
and Methodology (ISCTM), 12-13 September 2024, San Diego CA Poster
Presentation

 

Enquiries:

 

 Cambridge Cognition Holdings plc                    Tel: 012 2381 0700

 Dr Steven Powell, Chairman

 Hudson Sandler (Financial PR and IR)                 Tel: 020 7796 4133

 Dan de Belder / Hattie Dreyfus / Harry Griffiths    cog@hudsonsandler.com (mailto:cog@hudsonsandler.com)

 Panmure Liberum Limited (NOMAD and Joint Broker)     Tel: 020 7886 2968

 Will Goode / Freddy Crossley / Mark Rogers          (Corporate Finance)

 Rupert Dearden                                      (Corporate Broking)

 Dowgate Capital Limited (Joint Broker)

 David Poutney / James Serjeant                      Tel: 020 3903 7715

 

Notes to Editors

 

About Cambridge Cognition

 

Cambridge Cognition is a leading technology company specializing in digital
health products that advance brain health research and treatment. The Company
offers three core products: CANTAB® assessments, which provide scientifically
validated, highly sensitive, precise, and objective measures of cognitive
function correlated to neural networks; A flexible and proven eCOA platform,
with a large library of instruments, enabling efficient study set up and
scalable data capture; and Quality Assurance Tools that ensure data integrity
by automatically detecting deviations in administration and scoring, saving
time and money. Together, these products improve clinical trial outcomes,
enable early patient identification, and enhance global efficiency in
healthcare and pharmaceuticals.

 

For further information visit: https://cambridgecognition.com/
(https://cambridgecognition.com/)

 

About Dr Rachel Newsome

 

Rachel joined Winterlight Labs in 2021 as a Product Manager for the speech
data collection application. Following the company's acquisition by Cambridge
Cognition in 2023, she now contributes to the voice analytics product and
AQUA, the core tool behind Cambridge Cognition's central monitoring solutions.

Rachel received her PhD in Cognitive Neuroscience from the University of
Toronto, focusing on memory and perception in amnesia and dementia. She
completed a postdoctoral fellowship at the Rotman Research Institute, where
she researched learning processes following stroke and brain injury, employing
neuroimaging and cognitive experiments to explore how these patients can
acquire new information.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAQKKBKCBDDFKN